D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
48,750
+800 (1.67%)
Mar 28, 2025, 3:30 PM KST
47.73%
Market Cap 515.19B
Revenue (ttm) 11.44B
Net Income (ttm) -28.62B
Shares Out 10.57M
EPS (ttm) -2,823.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 87,949
Average Volume 147,594
Open 48,700
Previous Close 47,950
Day's Range 47,800 - 49,850
52-Week Range 25,100 - 64,000
Beta n/a
RSI 42.25
Earnings Date Mar 28, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.